Intra-tumoral Ipilimumab Plus Intravenous Nivolumab Following the Resection of Recurrent Glioblastoma
Status:
Recruiting
Trial end date:
2023-11-17
Target enrollment:
Participant gender:
Summary
Phase I clinical trial on intra-tumoral ipilimumab plus intravenous nivolumab following the
resection of recurrent glioblastoma.
The aim of this clinical trial is to exploit the potential synergy of combined intra-tumoral
CTLA-4 and systemic PD-1 blockade while minimizing the risk for increased immune-related
toxicity by intratumoral administration of the CTLA-blocking mAb ipilimumab following the
resection of the recurrent glioblastoma.